Form 4: Director Bob Oliver Receives RSU Grant at Exelixis

Exelixis, Inc. director Bob Oliver was granted 8,367 restricted stock units as part of the company's 2017 Equity Incentive Plan.

Summary

• Director Bob Oliver acquired 8,367 restricted stock units (RSUs) on May 27, 2026.
• The grant was issued under the Exelixis, Inc. 2017 Equity Incentive Plan.
• Each RSU represents the economic equivalent of one share of common stock.
• The total beneficial ownership for the director following this transaction is 29,487 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on company operations or financial strategy.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is subject to the director's continuous service through the May 27, 2027, vesting date.

Future Outlook

The RSUs are scheduled to vest 100% on May 27, 2027, contingent upon the director's continued service.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to align director incentives with company performance in the biotechnology sector.

Comparison to Industry Standards

• The use of RSU grants for director compensation is consistent with standard practices among mid-to-large cap biotechnology firms.
• The one-year cliff vesting schedule is a common retention mechanism for board members in the industry.

Stakeholder Impact

• Minor dilution impact upon future vesting of RSUs.

Next Steps

• Vesting of the 8,367 RSUs on May 27, 2027.

Key Dates

Keywords

Exelixis, EXEL, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation